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Abstract
The distinction between Burkitt lymphoma (BL) and diffuse large B-cell lymphoma (DLBCL), two types of mature aggressive
B-cell lymphomas that require distinct treatments, can be difficult because of forms showing features intermediate between
DLBCL and BL (here called BL/DLBCL). They can be discriminated by the presence of c-myc translocations characteristic of
BL. However, these are not exclusive of BL and when present in DLBCL are associated with lower survival. In this study, we
show that Epstein-Barr virus-induced gene 3 (EBI3) is differentially expressed among BL and DLBCL. Analysis of gene
expression data from 502 cases of aggressive mature B-cell lymphomas available on Gene Expression Omnibus and
immunohistochemical analysis of 184 cases of BL, BL/DLBCL or DLBCL, showed that EBI3 was not expressed in EBV-positive
or -negative BL cases, whereas it was expressed by over 30% of tumoral cells in nearly 80% of DLBCL cases, independently of
their subtypes. In addition, we show that c-myc overexpression represses EBI3 expression, and that DLBCL or BL/DLBCL
cases with c-myc translocations have lower expression of EBI3. Thus, EBI3 immunohistochemistry could be useful to
discriminate BL from DLBCL, and to identify cases of BL/DLBCL or DLBCL with potential c-myc translocations.
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Introduction
Burkitt’s lymphoma (BL) and diffuse large B-cell lymphoma
(DLBCL) are mature aggressive B-cell lymphomas whose
distinction can be tricky. Their diagnosis relies on the patient’s
clinical data and on specific features of the lymphoma including
morphology, immunophenotype, and cytogenetic abnormalities.
BL is a homogenous group characterized by c-myc overexpres-
sion as a result of c-myc gene translocation, and consequently
increased proliferation. This translocation juxtaposes the locus of
c-myc gene to one of the Ig loci (heavy chain, lambda or kappa
light chains) [1]. In contrast, DLBCL encompasses a heteroge-
neous group of B-cell lymphomas with clinical, morphological,
immunohistochemical and molecular subtypes [2,3]. Accurate
diagnosis of BL and DLBCL is essential because adequate
chemotherapy regimen differs between both types of lymphomas.
BL is cured by high intensity chemotherapy, whereas DLBCL is
usually treated by lower-dose chemotherapy regimens: cyclo-
phosphamide, doxorubicin, vincristine, and prednisone (CHOP),
in association with rituximab anti-CD20 antibody (R-CHOP)
[1,3–5].
Although Ig-myc translocation is the hallmark of BL, c-myc
translocations are also found in other lymphomas. In particular,
they are found in a subset (5 to 15%) of DLBCL and in a high
proportion of lymphomas that are borderline between BL and
DLBCL and were previously called « atypical BL » or « BL-like
lymphoma ». These latter lymphomas are now categorized as « B-
cell lymphomas, unclassifiable, with features intermediate between
DLBCL and BL » [6], and will be referred to as BL/DLBCL in
this study. In BL/DLBCL and DLBCL, c-myc translocations often
involve non-Ig partners and are associated with a complex
caryotype. Several studies have shown that these cases represent
aggressive forms with poor prognosis [7–12] and the most
appropriate treatments remain a matter of debate. In particular,
a recent study showed that, among DLBCL patients treated with
R-CHOP chemotherapy, those having c-myc gene rearrangements
had an inferior prognosis compared to those without c-myc
translocations, and it was suggested that treatment regimens
similar to those used in BL would be more appropriate for these
cases [11]. These observations highlighted the importance of
identifying cases of DLBCL with c-myc translocations. However,
cytogenetic studies are not systematically performed.
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24617In previous immunohistochemical studies, we showed that
Epstein-Barr virus (EBV)-induced gene 3 (EBI3), a molecule
related to the p40 subunit of interleukin (IL)-12 [13], exhibited a
restricted expression profile among B-cell lymphomas [14,15]. We
found that EBI3, which was originally characterized as a gene
induced in EBV-transformed B cells by the viral oncogene LMP1
[13,16], was also expressed in certain non-EBV-associated B-cell
lymphomas such as DLBCL. Indeed, EBI3 was found to be
expressed by tumoral cells in 18/22 cases of DLBCL [15], whereas
it was not expressed in 6/6 cases of EBV-positive BL [17],
consistent with the absence of LMP1 expression in EBV-associated
BL. Subsequently, a study of gene profiling by Dave et al [18]
showed that EBI3 was among the NF-kB regulated genes that
were selectively overexpressed in DLBCL compared to BL.
These observations prompted us to further analyze the
expression of EBI3 in large series of BL and DLBCL to clearly
establish its differential expression profile among both types of
lymphomas, and the usefulness of EBI3 immunohistochemistry for
their differential diagnosis. In addition, we investigated whether
EBI3 immunohistochemistry could be used as a tool to identify




Formalin-fixed paraffin-embedded tumorbiopsies from 184cases
of mature aggressive B-cell lymphomas diagnosed between 1987
and 2009 at Necker Hospital (Paris), Cochin Hospital (Paris) or the
Henri Becquerel Cancer Center (Rouen) were included in this
study. All cases were reviewed anew and classified according to the
World Health Organization 2008 lymphoma classification [6].
Tumors classified as BL (n=23) had both morphologic features and
an immunophenotype typical of BL (positivity for both CD10 and
Bcl6, and proliferation index measured by Ki67 positivity .90%).
EBV (EBER probe) was detected in 4/18 cases, and all but one of
cases were negative for Bcl2. Cases of DLBCL (n=138) were
classified into germinal center (GC) B-cell-like (GCB) or non-GCB
types, based on the differential immunodetection of CD10, Bcl6,
and MUM1, as previously described [15,19]. For these markers,
cases were considered positive if $30% of tumoral cells stained
positive. This category contains only one case of primary
mediastinal B-cell lymphoma (PMBL). The BL/DLBCL category
comprised cases (n=23) with morphological features that were
intermediate between DLBCL and BL, or cases with morphological
features of BL but a deviant immunophenotype based on Ki67,
Bcl6, and CD10 staining. A case of follicular lymphoma and its
transformed counterpart were also analyzed. In some cases (n=16),
frozen tissues were analyzed.
Translocations for c-myc were identified by conventional
cytogenetics using RHG-banding techniques on 24-hour cultures
of cells isolated from fresh tissue biopsies (103 cases), by
fluorescence in situ hybridization (FISH) using MYC dual color
break apart rearrangement probe (Vysis) performed on frozen or
paraffin-embedded tissues (13 cases) or both techniques (12 cases).
Cytogenetic data were obtained in 17/23 cases (74%) of BL, 88/
138 cases (64%) of DLBCL and in all BL/DLBCL cases. C-myc
translocations were detected in 17/17 of BL cases, 12/88 (14%) of
DLBCL cases and 19/23 (83%) of BL/DLBCL cases. The main
characteristics of the lymphomas are summarized on Table 1.
All tissues were collected for histological examination and
diagnosis purpose and were studied in accordance with the French
ethical laws for studies on human tissues and with the Declaration
of Helsinki. This study was approved by the institutional review
board of the hospitals and cancer center that provided tissue
samples and were involved in the study.
EBI3 immunohistochemistry
EBI3 immunostaining was performed on formalin-fixed paraf-
fin-embedded tissue sections. Sections were dewaxed, rehydrated
and subjected to antigen retrieval by heat pretratment using citrate
buffer. Endogeneous peroxidase activity was quenched with a
peroxide-methanol buffer. EBI3 was detected using 2G4H6 mouse
monoclonal antibody (IgG2a), the characterization and specificity
of which had been previously reported [20], at 2–4 mg/ml.
Specificity of the staining was controlled by testing in parallel an
isotype-matched control mAb (RPC5, IgG2a, Cappel Durham).
Binding of the primary antibody was detected by an indirect
avidin-biotin peroxidase technique (BioGenex) and DAB as
chromogen. Sections were counterstained with Mayer hematox-
ylin. Images were captured on a NanoZoomer 2.0-RS slide
scanner (Hamamatsu Corporation) and processed with NDP
Viewer. The percentage of EBI3-positive tumoral cells was
determined in a blinded fashion (without knowledge of c-myc
status) by two pathologists (JG and FL), independently.
Plasmids, cell line and transfection
An EcoRI fragment encoding an inducible c-myc-estrogen
receptor (Myc-ER) fusion protein was inserted in the EcoRI site
of pSG5 to construct pSG5-c-myc-ER plasmid. The green
fluorescent protein (GFP) expression vector, pEGFP-C1, was
obtained from Clontech.
Table 1. Characteristics of mature aggressive B-cell lymphomas analyzed by immunohistochemistry.
c-myc translocation
No. of No. of cases
Diagnosis cases Subtype analyzed present absent
BL 23 GCB 23 (100%) 17 17 (100%) 0
BL/DLBCL 23 GCB 21 (91%) 21 17 (81%) 4 (19%)
non-GCB 0
not determined 2 (9%) 2 2 0
DLBCL 138 GCB 49 (35%) 33 7 (21%) 26 (79%)
non-GCB 85 (62%) 53 4 (8%) 49 (92%)
not determined 4 (3%) 2 1 1
doi:10.1371/journal.pone.0024617.t001
Differential Expression of EBI3 in BL and DLBCL
PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e24617Karpas 1106, a DLBCL cell line derived from a patient with a
mediastinal form of DLBCL, was purchased from the Deutsche
Sammlung von Mikroorganismen und Zemmkulturen Gmbh,
Germany. It is negative for EBV and does not carry c-myc
translocation. It was cultured in RPMI 1640 medium supple-
mented with 20% fetal calf serum, L-glutamine and antibiotics.
For transient expression, Karpas 1106 cells (5610
6 cells per
cuvette) were electroporated with pSG5 control plasmid or pSG5-
c-myc-ER together with GFP expression vector on a BioradGene
Pulser Xcell electroporator at 250 V and 500 mF in 200 mlo f
RPMI medium containing 10% fetal calf serum. Two hours after
electroporation (or at later time points in some cases), 4-
hydroxytamoxifen (4-OHT, Sigma-Aldrich) was added at a final
concentration of 200 nM - unless otherwise specified - to activate
c-myc-ER fusion protein. Although we did not observe any
significant effect of 4-OHT on EBI3 expression in Karpas 1106
cells (not shown), 4-OHT was added to both pSG5 control and
pSG5-c-myc-ER transfected cells to exclude a non-specific effect.
Sixteen to 40 hours after 4-OHT addition, GFP-positive cells were
isolated by electronic cell sorting on a FACSAria cytometer
(IRNEM cell sorting facility). GFP-positive cells from c-myc-ER
transfectants were verified to express c-myc-ER fusion protein by
western blot (not shown).
Real time quantitative PCR (RTqPCR)
Total RNA was isolated from purified GFP-positive transfected
cells or from 20 mm frozen tissues sections by TRIzol extraction
followed by DNAse I digestion, or by using the RNeasy Plus Micro
kit (Qiagen). RNA was reverse transcribed into cDNA using M-
MLV reverse transcriptase, and oligo(dT) or random hexamer
Figure 1. Differential expression profile of EBI3 gene in BL and DLBCL defined by molecular profiling. Individual data for EBI3 gene were
retrieved from series GSE4732 [18] (A, B), and pooled from series GSE4475 and GSE10172 [8,21] (C, D). Relative expression of EBI3 is shown using the
authors’ scale. On (A) and (C) EBI3 expression among the different molecular types defined by gene profiling is shown. On (B) and (D), the expression
of EBI3 in mBL is shown according to their original pathological diagnosis. p values are indicated. The horizontal bar indicates the mean. NS: not
significant; unclass: unclassifiable.
doi:10.1371/journal.pone.0024617.g001
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myc was performed using Taqman Universal PCR Master mix and
TaqManH gene expression assays. For each sample, triplicate
reactions were run for 40 cycles on Step One Plus thermal cycler
(Applied Biosystems). Levels of target mRNA were normalized
relative to levels of ß2-microglobulin mRNA, and relative mRNA
expression was calculated using the comparative cycle threshold
method.
Statistical analysis
Statistical analysis was performed by Mann-Whitney or
Student’ t test. Correlation was analyzed by Spearman test. A p
value,0.05 was considered to indicate statistical significance.
Results
BL and DLBCL, defined by molecular profiling, are
characterized by differential expression of EBI3 gene
First, we analyzed EBI3 gene expression level in gene profiling
studies performed in mature aggressive B-cell non-Hodgkin
lymphomas that were available on Gene Expression Omnibus
(GEO) of the National Center for Biotechnology Information.
Individual data for EBI3 were retrieved from the study from Dave
et al. [18] (GSE4732) and from two German studies (Hummel et al.
[8], GSE4475, and Klapper et al. [21], GSE10172). In these
studies, cases of adult or pediatric lymphomas that had originally
received a pathological diagnosis of BL, DLBCL, BL/DLBCL, or
high grade mature B-cell lymphomas, unclassifiable, had been
analyzed for gene expression and classified into molecular BL
(mBL) or non-mBL (consisting mainly of DLBCL and designed as
molecular DLBCL in ref [18], using classifiers that were specific to
Dave et al. study or to the German studies. These 3 studies totaled
111 cases of mBL and 391 cases of non-mBL. These latter were
further classified into GCB (n=148), activated B-cell like (ABC)
(n=143) and PMBL (n=33) subtypes, or left unclassified (n=67).
Data shown on Figure 1A and 1C indicated that EBI3 expression
significantly differed between mBL and each of the non-mBL
subtype (p,0.0001). Thus, EBI3 expression was low in all but one
cases of mBL, whereas most cases of non-mBL, either GCB, ABC,
PMBL, or unclassified, exhibited higher expression of EBI3 gene.
In Dave et al. study, cases of non-mBL of the GCB type were the
most heterogenous for EBI3 expression and contained the higher
proportion of cases with low expression. However, this feature was
not observed in the GCB non-mBL defined in the other studies,
possibly due to the different ways the classification was performed
in each study.
Over 50% of the cases - 28/53 (53%) (Figure 1B) and 43/57
(75%) (Figure 1D) -classified as mBL upon gene profiling by
microarray analysis were initially classified as BL/DLBCL,
DLBCL or aggressive NHL based on pathological diagnosis. Of
note, EBI3 level was equally low in classic BL and in cases that
were re-classified as mBL upon molecular profiling (Figure 1B and
1D).
Immunohistochemical analysis of EBI3 in BL and DLBCL
The differential expression profile of EBI3 observed among BL
and DLBCL defined by molecular profiling was next confirmed at
the protein level by analyzing by immunohistochemistry with anti-
EBI3 mAb, 23 cases of classic BL and 138 cases of DLCBL
(Figure 2A). No or rare EBI3-positive cells (1% positive tumoral
cells at the most) were detected in BL cases including both EBV-
positive or -negative cases. In contrast, numerous EBI3-positive
cells, most of which were tumoral cells, were detected in a large
proportion of DLBCL. These EBI3-positive tumoral cells
exceeded 50% in over 60% of DLBCL cases. When a cut-off for
positivity was set at $30% of tumoral cells (this cut-off will be used
Figure 2. Immunohistochemical analysis of EBI3 expression in classic BL and DLBCL. (A) Percentage of EBI3-positive tumoral cells in BL
and DLBCL cases analyzed by EBI3 immunohistochemistry. (B) Frequency of EBI3-positive or -negative cases among BL and DLBCL, when positivity is
defined by $30% stained tumoral cells. (C) Distribution of EBI3-positive and -negative cases among DLBCL of the GCB or non-GCB subtypes.
doi:10.1371/journal.pone.0024617.g002
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considered positive for EBI3, whereas all BL cases were negative
(Figure 2B). When classified by immunohistochemistry in GCB
and non-GCB subtypes, representing the equivalents of the GCB
and ABC cell types defined by molecular profiling, 71% of the
GCB cases were positive for EBI3, while this percentage reached
85% among non-GCB cases (Figure 2C), indicating a slight over-
representation of EBI3-negative cases among GCB DLBCL, in
line with the molecular data from Dave et al. study.
Taken together, these data obtained in a large series of BL and
DLBCL indicate that positivity for EBI3 in tumoral cells strongly
argues against a diagnosis of BL, while it is in favor of a DLBCL
diagnosis.
Lymphomas harboring c-myc translocations are
characterized by lower expression of EBI3 gene
In the studies from Hummel et al. [8] and Klapper et al. [21],
cytogenetic data for the c-myc gene were available for a large number
of cases (n=245). Therefore, we investigated in patients that did not
fulfill the mBL signature, i.e. cases that were classified as non-mBL or
cases that could not be classified into mBL or non-mBL and were
called « intermediate forms », if the presence of c-myc gene
rearrangements (21% of the cases) affected EBI3 expression. Indeed,
we observed that lymphomas, other than mBL, harboring myc-
translocations had higher expression of c-myc, as expected, but also
lower expression of EBI3 (p,0.0001) (Figure 3A). This observation
wastruewhethercaseshadc-myctranslocations involving Ig or non-Ig
genes. In these lymphomas, an inverse correlation between EBI3 and
c-myc expression was observed (Figure 3B)(n=194, p=0.0007). This
inverse correlation was also observed when this analysis was
performed by selecting cases that were originally classified as BL/
DLBCL upon pathological diagnosis (Figure 3C)(n=39, p=0.0009).
Collectively, these data suggested that EBI3 expression level
could be indicative of the level of c-myc expression and could
constitute a marker to identify lymphomas with c-myc transloca-
tions, among both BL/DLBCL and DLBCL.
Overexpression of c-myc represses EBI3 gene expression
The inverse correlation observed between EBI3 and c-myc
expression suggested that c-myc overexpression may repress EBI3
expression. To test this hypothesis, we used an in vitro assay by
overexpressing an inducible c-myc-ER fusion protein that has
Figure 3. Analysis of EBI3 gene expression according to the presence or absence of c-myc translocation. Individual data for EBI3 and c-
myc were retrieved from GSE4475 and GSE10172 series [8,21]. On (A), the expression of EBI3 and of c-myc was analyzed according to the presence or
not of c-myc translocations involving an Ig locus (Ig-myc) or not (non-Ig-myc). « others » designated lymphomas other than mBL, ie lymphomas
classifed as non-mBL and lymphomas that could not be classified as mBL or non-mBL. On (B), EBI3 expression among all lymphomas other than mBL
is represented according to that of c-myc. On (C), EBI3 expression among lymphomas that had initially received a pathological diagnosis of BL/DLBCL
is shown according to that of c-myc. p values are indicated. NS: not significant.
doi:10.1371/journal.pone.0024617.g003
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protein is retained in the cytoplasm as an inactive form and
translocate to the nucleus when cells are exposed to a modified
estrogenic ligand, 4-OHT. The Karpas 1106 DLBCL cell line,
that expresses EBI3, was transiently transfected with a GFP
reporter plasmid, and either pSG5 vector control or pSG5-c-myc-
ER , and cultured in the presence of 4-OHT. Twenty hours post-
transfection, GFP-positive cells were isolated by cell sorting and
analyzed for EBI3 expression by RTqPCR. Data shown on
Figure 4A indicate that overexpression of c-myc results in
statistically significant decrease of EBI3 expression (40% decrease
on average, p,0.0001). This effect was specific : it was not
observed when 4-OHT was not added to the culture (Figure 4B)
and was dose-dependent, as it gradually increased with 4-OHT
concentration (Figure 4C). This negative effect of c-myc fusion
protein overexpression on EBI3 expression was observed at all
time points tested upon 4-OHT addition (Figure 4D). Treatment
of transfected cells with 4-OHT for 16 or 24 hours led to a similar
decrease in EBI3 expression, while treatment for 40 h resulted in a
somewhat higher decrease. Altogether, these data indicate that c-
myc overexpression represses EBI3 expression.
Immunohistochemical analysis of EBI3 expression in BL/
DLBCL and DLBCL characterized for c-myc gene
rearrangement
Next, we investigated in DLBCL and BL/DLBCL whether their
positivity ornegativity forEBI3,assessed by immunohistochemistry,
correlated with the absence or presence of c-myc translocation. This
analysis was performed in 88 of the 138 cases of DLBCL tested for
EBI3 for which cytogenetic data were available and in 23 cases of
BL/DLBCL, all characterized for c-myc translocation, that we tested
for EBI3 by immunohistochemistry. c-myc translocations were
present in 12/88 (14%) of DLBCL cases and 19/23 (83%) of BL/
DLBCL cases.
Cases with c-myc translocation were not equally distributed
among EBI3-positive or -negative cases (Figure 5A and Figure 6).
Indeed, most EBI3-positive cases (67/71, 94%) did not have c-myc
translocation. In contrast, while 28% of total cases had a c-myc
translocation, this percentage reached 68% among EBI3-negative
cases. The correlation between negativity for EBI3 and the
presence of c-myc gene rearrangement was higher in BL/DLBCL
than in DLBCL. Indeed, 16/17 (94%) of EBI3-negative BL/
DLBCL had a translocation for c-myc, while 12/23 (52%) of EBI3-
negative DLBCL had c-myc gene rearrangement. Nevertheless, the
frequency of c-myc translocation was 3.7 higher in EBI3-negative
DLBCL cases compared to all DLBCL cases. Thus, consistent
with the previous observations, positivity for EBI3, as determined
by immunohistochemistry, argues against the presence of c-myc
translocation. Conversely, negativity for EBI3 among BL/DLBCL
or DLBCL indicates a higher probability for the presence of c-myc
translocation, especially in BL/DLBCL cases.
Frozen tissue was available in 16 of the 88 cases with cytogenetic
data. These cases included 10 cases without c-myc translocation (all
DLBCL cases) that contained from 50R90% EBI3-positive
Figure 4. In vitro effect of c-myc overexpression on EBI3 expression level. Karpas 1106 cell line was transfected with a GFP reporter plasmid
together with c-myc-ER expression vector or a control vector and cultured for various times in the absence or presence of 4-OHT. EBI3 expression in
GFP-positive cells isolated from vector control transfected cells (Col) or c-myc-ER transfected cells (c-myc-ER) was analyzed by RTqPCR. In (A),
transfected cells were cultured for 20 hours in the presence of 4-OHT (200 nM). Data are expressed as mean 6 SEM from 3 independent transfections.
p value is indicated. In (B), cells were cultured for 20 hours in the absence or presence of 4-OHT (200 nM). In (C), cells were cultured with increasing
concentrations of 4-OHT. The expression of EBI3 in c-myc-ER transfected cells relative to that measured in control tranfected cells is represented. The
percentage of decrease is indicated. A higher concentration of 4-OHT (1 mM) did not result in higher repression of EBI3 expression (not shown). In (D),
4-OHT was added to the transfected cells for the last 16, 24 or 40 h of the culture. In (B)–(D), a representative experiment is shown.
doi:10.1371/journal.pone.0024617.g004
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with c-myc translocation (5 BL/DLBCL cases and one DLBCL
case) that contained ,5% EBI3-positive tumoral cells. RTqPCR
analysis confirmed that cases with c-myc translocation, expressing
higher levels of c-myc (Figure 5B, bottom graph, p=0.04) and
classified as negative by EBI3 immunohistochemistry, had low
EBI3 gene expression compared to cases without c-myc transloca-
tions classified as EBI3-positive (Figure 5B, top graph, p=0.005).
On average, the EBI3/c-myc expression ratio was 27-fold higher in
lymphomas without c-myc translocations than in lymphomas with
c-myc translocation (Figure 5C, p,0.005). These data indicate that
EBI3 expression, analyzed at the protein level by immunohisto-
chemistry or at the mRNA level, inversely correlates with c-myc
expression.
In vivo downregulation of EBI3 expression by tumoral
cells upon c-myc translocation
C-myc translocations can occur as secondary oncogenic event in
follicular lymphomas that transform into DLBCL. In a previous
report, we had observed that in follicular lymphomas, EBI3 was
expressed by tumoral cells, mainly large cells, at a variable level
that could reach up to 30% of tumoral cells [15]. To further
investigate the in vivo effect of c-myc translocation on EBI3
expression, we analyzed the expression of EBI3 by immunohis-
tochemistry in a case of follicular lymphoma that had acquired c-
myc translocation during transformation (Figure 7). Whereas a
substantial fraction of tumoral cells stained positive for EBI3 in the
follicular lymphoma (Figure 7a), tumoral cells were all negative for
EBI3 in the c-myc-positive transformed counterpart (Figure 7b).
This in vivo observation further supports our in vitro data showing
that c-myc overexpression downregulates EBI3 expression.
Discussion
DLBCL is a heterogeneous lymphoma with various subtypes
characterized by different gene expression profiles [23–25], which
hampers the identification of markers that are both specific to
DLBCL and common to all subtypes. The analysis of data from
gene profiling studies available on GEO, and our data obtained by
immunohistochemistry, all concurr to establish that DLBCL and
BL are characterized by a differential expression profile of EBI3.
In particular, our immunohistochemical analysis indicates that,
whereas EBI3 was not expressed at significant levels in all BL
cases, a large fraction of tumoral cells was positive for EBI3 in
,80% of DLBCL cases. In addition, we showed that an inverse
correlation was observed between EBI3 expression and the
presence of a c-myc translocation. Thus, 94% EBI3-negative BL/
DLBCL cases exhibited c-myc translocations. In addition, while c-
myc translocations were found in 14% of DLBCL cases in our
series, this percentage increased to 52% among EBI3-negative
cases. As mentioned earlier, the identification of c-myc transloca-
tions among BL/DLBCL and DLBCL is important, given that
cases with c-myc translocations are associated with poor prognosis
and decreased survival [8,9,11,12]. Despite a recent report
suggesting that c-myc translocation could be identified by analyzing
c-myc subcellular localization [26], the overexpression of c-myc
resulting from the translocation of the gene remains difficult to
assess by immunohistochemistry. Thus, EBI3 immunohistochem-
istry, possibly in conjunction with c-myc staining, performed
routinely in all cases of BL, DL/DLBCL and DLBCL, could not
only help to discriminate BL and DLBCL, but also be useful to
identify cases of BL/DLBCL and DLBCL with potential c-myc
translocation and target these cases for further cytogenetic analysis
by FISH. Because of practical considerations, FISH analysis is
usually not routinely performed in all cases of DLBCL. Given that
c-myc translocations are mostly found among EBI3-negative
DLBCL cases which account for about one fifth of all DLBCL
cases, targeting EBI3-negative cases for FISH analysis would allow
to reduce by 80% the total number of DLBCL to test.
Figure 5. Effect of c-myc translocation on EBI3 expression in
lymphomas. (A) The distribution of cases with or without c-myc
translocations among all BL/DLBCL and DLBCL cases, or among EBI3-
negative versus EBI3-positive cases, is shown. EBI3 positivity ($30%
stained tumoral cells) was assessed by immunohistochemistry. (B) The
relative expression of EBI3 and c-myc (normalized to ß2m expression)
was determined by RTqPCR in frozen tissues from 10 cases of B-cell
lymphomas without c-myc translocation that were positive for EBI3 by
immunohistochemistry and 6 cases of B-cell lymphomas without c-myc
translocation that were negative for EBI3. (C) The ratio of EBI3/c-myc
expression in the cases analyzed is (B) is represented. p values are
indicated.
doi:10.1371/journal.pone.0024617.g005
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remain to be established. In normal B cells, EBI3 is expressed at
precise stages of B-cell differentiation. It is not expressed in naive B
cells and in centroblasts, and is essentially expressed by a subset of
germinal center B cells corresponding to activated centrocytes or
cells at an early stage of plasma cell differentiation [15,27]. In
activated normal B cells, EBI3 expression is positively regulated by
NF-kB activation [15]. In tumoral B cell lines, including DLBCL
cell lines, EBI3 expression has been shown to be dependent on
NF-kB activation, and in EBV-transformed B cells to be induced
by LMP1 in an NF-kB dependent manner [14,16,28]. Thus, the
absence of EBI3 expression in BL may be due to its stage of
differentiation (centroblast), its lack of NF-kB activation, the
absence of LMP1 expression (for EBV-positive cases) or its high
expression of c-myc that could repress EBI3 induction. Of note,
the only mBL showing significant expression of EBI3 (Figure 1C)
was a case that did not exhibit c-myc translocation.
In DLBCL, both its stage of differentiation and the activation of
NF-kB, may account for EBI3 expression. Previous studies have
shown that DLBCL originates from GC (GCB subtype) or post-
GC (ABC subtype) normal B cells [23]. The GCB subtype was
initially associated with low NF-kB activation, whereas the ABC
subtype was associated with high NF-kB activation [23]. However,
a more recent study has shown that not only 95% of ABC forms,
but also nearly 50% of GCB forms, are characterized by
substantial NF-kB activation [29]. Thus, in both GCB and ABC
subtypes, the activation of NF-kB may account for EBI3
expression. The higher proportion of GCB cases among EBI3-
negative cases supports this hypothesis.
Another factor regulating EBI3 expression in DLBCL is the
presence of c-myc translocations resulting in c-myc overexpression
that in turn can repress EBI3 expression. Indeed, c-myc
translocations were present in about half EBI3-negative DLBCL
Figure 6. Immunohistochemical analysis of EBI3 expression in BL, BL/DLBCL and DLBCL. Sections from a case of BL (a), 2 cases of BL/
DLBCL (b, c), and 2 cases of DLBCL (d, e) with or without c-myc translocation as indicated on each figure, were analyzed for EBI3 expression by
immunohistochemistry. An inverse correlation between the presence of c-myc translocation and the positivity for EBI3 in tumoral cells was observed.
Each picture is shown at the same magnification. The bar shown on (c) represents 50 mm.
doi:10.1371/journal.pone.0024617.g006
Figure 7. Immunohistochemical analysis in a case of follicular
lymphoma and its transformed counterpart. Sections from a
follicular lymphoma (a) that subsequently acquired a c-myc transloca-
tion and transformed into a DLBCL (b) were analyzed for EBI3
expression by immunohistochemistry. The bar represents 50 mm.
doi:10.1371/journal.pone.0024617.g007
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expression may be a direct effect or could result from the known
negative effect of c-myc on NF-kB effectors [30,31]. The
negativity for EBI3 expression among DLBCL cases may also be
due to the fact that some of them may arise from transformed
follicular lymphomas, an event that is not always diagnosed.
Previously, we have shown that EBI3 expression by tumoral cells is
lower in follicular lymphomas (from 1 to 30% positive tumoral
cells at the most) than in DLBCL [15], and remains lower (less
than 30% positive tumoral cells) in established transformed
follicular lymphomas (our unpublished data). This hypothesis is
also supported by the fact that EBI3 gene expression in the
German series analyzed here [8,21] was on average lower in
DLBCL with t(14;18) translocation (not shown).
The biological significance of EBI3 expression in DLBCL
remains to be investigated. EBI3 can associate with two different
partners, p28, to form the heterodimeric cytokine IL-27, or p35, to
form IL-35 [32,33]. Both cytokines have been described as
important negative regulators of T-cell responses [34–36]. In a
previous immunohistochemical analysis, p28 was not detected in
tumoral cells of DLBCL cases [15]. p28, the expression of which
was analyzed only in a subset of the lymphomas of the gene
profiling studies studied here, did not show increased expression in
DLBCL compared to BL. p35 gene was present on the gene chips
used in the 3 studies, and analysis of its expression profile showed
increased expression in DLBCL, especially those of the ABC
subtype, compared to BL (our unpublished data). Whether IL-35
protein is produced in these lymphomas and contributes to their
higher aggressiveness possibly by suppressing local anti-tumoral
immune responses, remains to be established.
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